-
公开(公告)号：US20190284530A1
公开(公告)日：2019-09-19
申请号：US16354100
申请日：2019-03-14
发明人： Micah BENSON , Jason Merkin , Gregory V. Kryukov , Solomon Martin Shenker , Michael Schlabach , Noah Tubo , James Martin Kaberna, II
IPC分类号： C12N5/0783 , C07K14/725 , A61K35/17 , A61P35/00 , A61P35/04 , C12N9/22 , C12N15/113 , C12N15/11 , C07K16/28 , C07K16/32 , C07K14/705
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20200181610A1
公开(公告)日：2020-06-11
申请号：US16791273
申请日：2020-02-14
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO
IPC分类号： C12N15/11 , C12N15/113 , A61K35/17 , C07K14/705 , C07K14/725 , C07K16/32 , C07K16/28 , C12N5/0783 , C12N9/22 , A61P35/04 , A61P35/02 , A61P35/00
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20190284553A1
公开(公告)日：2019-09-19
申请号：US16354102
申请日：2019-03-14
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO
IPC分类号： C12N15/11 , A61K35/17 , A61P35/00 , A61P35/02 , A61P35/04 , C12N9/22 , C12N15/113 , C12N5/0783 , C07K16/28 , C07K16/32 , C07K14/725 , C07K14/705
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20210071140A1
公开(公告)日：2021-03-11
申请号：US16951310
申请日：2020-11-18
发明人： Micah BENSON , Jason MERKIN , Gregory V. KRYUKOV , Solomon Martin SHENKER , Michael SCHLABACH , Noah TUBO , James Martin KABERNA, II
IPC分类号： C12N5/0783 , A61K35/17 , A61P35/00 , A61P35/04 , C12N9/22 , C12N15/113 , C12N15/11 , C07K16/28 , C07K16/32 , C07K14/705 , C07K14/725
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
公开(公告)号：US20200347386A1
公开(公告)日：2020-11-05
申请号：US16781732
申请日：2020-02-04
发明人： Micah BENSON , Michael SCHLABACH , Gregory KRYUKOV , Anne Louise CADZOW , Isabelle Fleur LE MERCIER , Frank STEGMEIER
摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
-
-
-
-
搜索结果
5 条记录 (耗时 0.017 秒)
